Human Recombinant CD37 protein, ECD, hFc Tag (V2LY-0526-LY2818)

Name: Human Recombinant CD37 protein, ECD, hFc Tag
SKU: V2LY-0526-LY2818
Rating: 5 (1 reviews)

See all CD37 antibodies

Compare Online Inquiry

Datasheet

SDS

Request for COA

Datasheet Target References Q & As Review & reward Protocols Associated Products

Basic Information

Expressed Host

HEK293 Cells

Protein Species

Human

Tag

hFc Tag

Protein Construction

This product is Human Recombinant CD37 protein, ECD, hFc Tag consist of Amino Acid: 112-241 and predicts a molecular mass of 41.62 kDa.

Molecule Mass

41.62 kDa

Protein Domain

ECD

Verified

HPLC

Sequence

Amino Acid: 112-241

Species

Human

Formulations & Storage [For reference only, actual COA shall prevail!]

Purity

>95% as determined by SDS-PAGE.>95% as determined by SEC-HPLC.

Endotoxin

Please contact us for more information.

Format

Lyophilized

Reconstitution

Allow the vial and reconstitution buffer to equilibrate to room temperature. Briefly centrifuge or tap down the vial to ensure that all lyophilized powder is collected at the bottom of the vial. For the reconstitution of this product, we recommend adding PBS or sterile water to achieve a final antibody concentration of 1 mg/mL. Allow the vial to reconstitute for 10-15 minutes at room temperature with gentle agitation. Avoid vigorous shaking that can cause foaming and antibody denaturation. Aliquot into volumes based on your experiment and store liquid protein at -20°C or -80°C for long time.

Buffer

Lyophilized from sterile Tris, NaCl, Glutathione, EDTA, DTT, PMSF, Glycerol

Preservative

None

Storage

Samples are stable for up to twelve months from date of receipt at -20°C to -80°C. Store it under sterile conditions at -20°C to -80°C. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.

More Infomation

Target

Full Name

CD37 Molecule

Cellular Location

Membrane

Topology

Cytoplasmic: 1-17
Helical: 18-38
Extracellular: 39-59
Helical: 60-74
Cytoplasmic: 75-85
Helical: 86-111
Extracellular: 112-241
Helical: 242-266
Cytoplasmic: 267-281

Okuno, S., Adachi, Y., Terakura, S., Julamanee, J., Sakai, T., Umemura, K., ... & Kiyoi, H. (2021). Spacer Length Modification Facilitates Discrimination between Normal and Neoplastic Cells and Provides Clinically Relevant CD37 CAR T Cells. The Journal of Immunology.

van der Horst, H. J., Oostindie, S. C., Cillessen, S. A., Gelderloos, A. T., Overdijk, M. B., Nijhof, I. S., ... & Mutis, T. (2021). Potent preclinical efficacy of DuoHexaBody-CD37 in B-cell malignancies. Hemasphere, 5(1).

Yan, X., Zhou, Q., Zhu, H., Liu, W., Xu, H., Yin, W., ... & Ren, C. (2021). The clinical features, prognostic significance, and immune heterogeneity of CD37 in diffuse gliomas. Iscience, 24(11), 103249.

Oostindie, S. C., van der Horst, H. J., Kil, L. P., Strumane, K., Overdijk, M. B., van den Brink, E. N., ... & Breij, E. C. (2020). DuoHexaBody-CD37®, a novel biparatopic CD37 antibody with enhanced Fc-mediated hexamerization as a potential therapy for B-cell malignancies. Blood cancer journal, 10(3), 1-13.

Bobrowicz, M., Kubacz, M., Slusarczyk, A., & Winiarska, M. (2020). CD37 in B cell derived tumors—more than just a docking point for monoclonal antibodies. International Journal of Molecular Sciences, 21(24), 9531.

Zhang, Q., Han, Q., Zi, J., Song, C., & Ge, Z. (2020). CD37 high expression as a potential biomarker and association with poor outcome in acute myeloid leukemia. Bioscience reports, 40(5), BSR20200008.

Malenge, M. M. (2020). Combination of anti-CD37 radioimmunotherapy with anti-CD20 immunotherapy and small molecule inhibitors to improve therapy of non-Hodgkin lymphoma.

Oostindie, S. C., Van Der Horst, H. J., Lindorfer, M. A., Cook, E. M., Tupitza, J. C., Zent, C. S., ... & Taylor, R. P. (2019). CD20 and CD37 antibodies synergize to activate complement by Fc-mediated clustering. haematologica, 104(9), 1841.

Payandeh, Z., Noori, E., Khalesi, B., Mard-Soltani, M., Abdolalizadeh, J., & Khalili, S. (2018). Anti-CD37 targeted immunotherapy of B-Cell malignancies. Biotechnology letters, 40(11), 1459-1466.

Ask a question We look forward to hearing from you.

0 reviews or Q&As

Purchasing FAQs
Technical FAQs

Have you used Human Recombinant CD37 protein, ECD, hFc Tag?
Submit a review and get a Coupon or an Amazon gift card. 20% off Coupon

$30 eGift Card
Submit a review

Please try the standard protocols which include: protocols, troubleshooting and guide.

Enzyme-linked Immunosorbent Assay (ELISA)
Flow Cytometry
Immunofluorescence (IF)
Immunohistochemistry (IHC)
Immunoprecipitation (IP)
Western Blot (WB)
Enzyme Linked Immunospot (ELISpot)
Proteogenomic
Other Protocols

Alternative Versions

Mouse Recombinant CD37 protein, ECD, hFc Tag (CAT#: V2LY-0526-LY8005)

Related Products

Rabbit Anti-CD37 Recombinant Antibody (CBYJT-1092) (CAT#: CBMAB-T0102-YJ)

Mouse Anti-CD37 Recombinant Antibody (CBFYC-1244) (CAT#: CBMAB-C1302-FY)

Mouse Anti-CD37 Recombinant Antibody (CBT2629) (CAT#: V2LY-0625-LY2249)

Mouse Anti-CD37 Recombinant Antibody (IPO-24) (CAT#: CBMAB-AP1056LY)

Mouse Anti-CD37 Recombinant Antibody (CBT299) (CAT#: V2LY-0625-LY3620)

Rabbit Anti-CD37 Recombinant Antibody (CBYJT-1091) (CAT#: CBMAB-T0101-YJ)

Mouse Anti-CD37 Recombinant Antibody (CBFYC-1243) (CAT#: CBMAB-C1301-FY)

Mouse Anti-CD37 Recombinant Antibody (CBYJT-1093) (CAT#: CBMAB-T0103-YJ)

Mouse Recombinant CD37 protein, ECD, hFc Tag (CAT#: V2LY-0526-LY8005)

Human Anti-CD37 Recombinant Antibody (CBXC-0826) (CAT#: CBMAB-C1940-CQ)

Isotype control

For research use only. Not intended for any clinical use.

Custom Antibody Labeling

We also offer labeled antibodies developed using our catalog antibody products and nonfluorescent conjugates (HRP, AP, Biotin, etc.) or fluorescent conjugates (Alexa Fluor, FITC, TRITC, Rhodamine, Texas Red, R-PE, APC, Qdot Probes, Pacific Dyes, etc.).

Online Inquiry

Request bulk or custom quote Second antibody and isotype control

Contact us

Tel: (USA)
(UK)
Fax:

Global Locations

Email:

Online Inquiry